Drug Profile
Research programme: Hsp90/F1F0-ATPase inhibitors - Ergon Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ergon Pharmaceuticals
- Class
- Mechanism of Action Adenosine triphosphatase inhibitors; Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 02 May 2006 Preclinical trials in Cancer in USA (unspecified route)